Virology, as we have seen during the COVID-19 pandemic, is an excellent candidate for virtual trials. The vast majority of symptomatic patients recover at home, but most clinical testing is happening in hospitals. Virtual trials reduce risks of disease transmission while more closely representing the real-world situations of participants. ObvioHealth’s platform and app enables the seamless enrolling and engagement of patients who are experiencing and recovering from symptoms from the comfort of their homes.
Virology trials also have their own particular challenges; they require extreme vigilance in monitoring side effects and drug interactions while also needing to manage some patients’ tendencies to inflate symptoms.
ObvioHealth’s virtual platform and app are designed to address these issues. The combination of our technology and ongoing surveillance from our virtual clinical operations team to conduct virtual training and continuous symptom monitoring increases the likelihood of ensuring safety while generating honest and accurate reporting for better clinical outcomes.
Saint-Joseph’s Hospital of Paris and ObvioHealth partnered to study the prevalence and impact of COVID-19 among oncology patients.Read Press Release
We will conduct a randomized, double-blind, placebo-controlled hybrid study. Participants will enroll at a clinical site and be sent home with study drug and several devices to collect both telemetric information and patient-reported information in order to measure the safety and efficacy of the investigational treatment.Go to the Case Study
Our proprietary application brings clinical research into people’s homes, making it easier for them to participate, and easier for researchers to collect robust data sets which reflect real behaviors.
Recruitment is often a huge barrier to trial success. ObvioHealth uses digital targeting methods to find untapped populations. We identify the online behaviors that point to people with a positive pre-disposition for a specific trial and, because our studies are virtual, we are not geographically tied to a site location.
Once recruited, we enroll participants through virtual prescreening/screening and e-consent. This eliminates the burdensome cost of site retention and staffing requirements, and often shortens the recruitment period.
The ObvioHealth platform and app incorporates multiple data capture technologies to adapt to the needs of any given trial. These include simple survey-type completion of questionnaires and diaries, image, video and audio capture and use of wearables. Complementary data collection methods ensure more robust data real world outcomes.
Our platform makes it easy to trigger, track and manage products and payment of incentives. ObvioHealth can reimburse participants with the stipend program that is fully virtual. We ship any needed study supplies or devices directly to the participant’s home.
An important advantage of ObvioHealth’s app is the real time remote monitoring of medication adherence and potential adverse events. Our escalating system of reminders and immediate AE/SAE detection make our studies safer, while also improving medication adherence.
Our easy-to-use, convenient app makes it easier for people to remain compliant. There is little to no time wasted travelling to clinical sites, so there are fewer dropouts. All of this means that studies end on time or ahead of schedule. And because participants are able to report more real world and real time experiences, the resulting data is more accurate and reliable.